Novo Nordisk shares fall further as new CEO faces US challenges
COPENHAGEN, DENMARK (Reuters) -Shares in Wegovy maker Novo Nordisk (NVO, NOVO-B.CO)continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker’s value. Novo Nordisk on Tuesday slashed…